A $30 million milestone fee is expected in the near term under the $1 billion deal between the firms.

Alnylam Pharmaceuticals achieved a $20 million technology transfer milestone from Takeda Pharmaceutical Company (as per the agreement formed between the companies in May 2008). This payment is related to the transfer of Alnylam’s platform technology including documents, materials, and know-how to Takeda for the development of RNAi therapeutics.

Alnylam received an initial payment of $100 million and stands to earn another $30 million as a technology transfer milestone fee in the near term. The strategic alliance formed between the firms is valued at over $1 billion in milestones related to R&D and commercialization.

Besides gaining access to Alnylam’s RNAi technology platform for immediate use in oncology and metabolic disorders, Takeda also became the company’s Asian partner for RNAi therapeutics for the next five years.

Previous articleAntisoma Gains Rights to Anticancer Agents from The Institute of Cancer Research
Next articleNCCN to Explore Other Indications for Metastatic Breast Cancer Drug from Abraxis and AstraZeneca